Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma
Mano Nakamura(King's College London), Sophia N. Karagiannis(King's College London), Daniele Scotto(King's College London), James Spicer(King's College London), Heather J. Bax(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Sam Sollie(King's College London), Niklas Hammar(Karolinska Institutet), Sophia Tsoka(King's College London), A. Winship(Guy's and St Thomas' NHS Foundation Trust), Katie E. Lacy(King's College London), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), R. J. C. Harris(King's College London), Sharmistha Ghosh(Guy's and St Thomas' NHS Foundation Trust), E. Amiri Souri(King's College London), Göran Walldius(Karolinska Institutet), Mieke Van Hemelrijck(Ghent University Hospital)
Cited by 27
Related Papers
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|602
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
|Journal of the American College of Cardiology|2018|465
Targeting folate receptor alpha for cancer treatment
|Oncotarget|2016|447
Prevalence and demography of transsexualism in Belgium
|European Psychiatry|2007|306